Sleep difficulties are emerging as a risk factor for dementia. This study examined the effect of sleep and amyloid deposition on cognitive performance in cognitively normal adults. Sleep efficiency was determined by actigraphy. Cerebrospinal fluid Ab 42 levels <500 pg mL À1 , indicating amyloid deposition, was present in 23 participants. Psychometric tests included the Free and Cued Selective Reminding Test, Trail Making Test A and B, Animal Fluency, Letter Number Sequencing, and the Mini Mental State Examination. The interaction term of sleep efficiency and amyloid deposition status was a significant predictor of memory performance as measured by total Selective Reminding Test scores. While Trail Making Test B performance was worse in those with amyloid deposition, sleep measures did not have an additive effect. In this study, amyloid deposition was associated with worse cognitive performance, and poor sleep efficiency specifically modified the effect of amyloid deposition on memory performance.
Sleep difficulties are emerging as a risk factor for dementia. This study examined the effect of sleep and amyloid deposition on cognitive performance in cognitively normal adults. Sleep efficiency was determined by actigraphy. Cerebrospinal fluid Ab 42 levels <500 pg mL À1 , indicating amyloid deposition, was present in 23 participants. Psychometric tests included the Free and Cued Selective Reminding Test, Trail Making Test A and B, Animal Fluency, Letter Number Sequencing, and the Mini Mental State Examination. The interaction term of sleep efficiency and amyloid deposition status was a significant predictor of memory performance as measured by total Selective Reminding Test scores. While Trail Making Test B performance was worse in those with amyloid deposition, sleep measures did not have an additive effect. In this study, amyloid deposition was associated with worse cognitive performance, and poor sleep efficiency specifically modified the effect of amyloid deposition on memory performance.
IN TROD UCTI ON
Optimal cognitive performance requires sleep. In crosssectional and longitudinal analyses, decreased sleep efficiency or poor sleep quality is associated with worse psychometric performance in cognitively normal older adults, especially in memory and executive functioning (Blackwell et al., 2006 (Blackwell et al., , 2011 Potvin et al., 2012) . Experimental models show that the sleep-wake cycle may regulate amyloid-beta levels in the cerebrospinal fluid (CSF; Kang et al., 2009; Xie et al., 2013) , suggesting poor sleep quality may affect the pathophysiological mechanisms of amyloid-beta deposition, an important step of Alzheimer's disease (AD) pathogenesis (Ju et al., 2014) . Subjective longer sleep latency and poor sleep quality have been associated with increased amyloid burden on positron emission tomography (Branger et al., 2016; Brown et al., 2016; Spira et al., 2013; Sprecher et al., 2015) . Decreased CSF amyloid-beta-42 (Ab 42 ) levels, an early biomarker of amyloid plaque deposition, have been associated with decreased sleep quality based on objective measures in cognitively normal middle-aged adults (Ju et al., 2013) . Additionally, the amyloid burden in the medial prefrontal cortex has been associated with impairment in non-rapid eye movement (REM) slow-wave activity, mediating impairment in memory consolidation (Mander et al., 2015) . No studies have examined the interaction between amyloid deposition and sleep on psychometric performance in cognitively normal adults. This study assessed the effect of sleep on cognitive performance, accounting for the presence of amyloid deposition based on CSF Ab 42 levels.
MAT ERIALS AN D METH ODS
Participants aged ≥45 years were drawn from longitudinal IRB-approved studies at the Washington University Knight Alzheimer's Disease Research Center as previously described (Ju et al., 2013) . The Washington University Human Research Protection Office approved all procedures, and written informed consent was obtained from all participants. Participants with psychometric testing within 1 year of CSF donation and within 3 years of actigraphy recording were included. All had normal cognition based on a Clinical Dementia Rating score of 0 (Morris, 1993) .
Trained psychometricians administered the psychometric tests. Free and total scores from the Free and Cued Selective Reminding Test (SRT) assessed memory, and scores from Trail Making Test A (TMA) and B (TMB), Animal Fluency, and Letter Number Sequencing assessed executive function (Pizzie et al., 2014 Cerebrospinal fluid Ab 42 levels, measured by enzyme-linked immunosorbent assay (INNOTEST; Immogenetics, Ghent, Belgium) as previously described, were analysed as a categorical variable (Ju et al., 2013) . A cutoff value of <500 pg mL À1 was used to indicate amyloid plaque deposition, based on prior studies correlating with cortical amyloid deposition on Pittsburgh Compound B imaging (Fagan et al., 2006 (Fagan et al., , 2009 . A fasting CSF was collected at the same time (07:00-08:00 hours) by lumbar puncture for all participants. Sleep was objectively measured using wrist actigraphy (Actiwatch2 â ; Philips Respironics, Murrysville, PA, USA) recording for 7-14 days (mean 13.6 AE 1.1 days). Participants pressed a button on the actigraphs to indicate bedtime and wake time, and also kept concurrent sleep diaries. Scoring of actigraphy was performed manually through Actiware (Philips Respironics) using a standardized protocol to reconcile actigraphic and sleep diary data, as previously described (Ju et al., 2013) , using wake threshold at the most sensitive 'low' setting of 20. Our primary sleep measure was sleep efficiency as a measure of sleep quality, as this measure was associated with amyloid deposition in a prior study (Ju et al., 2013 (Mezick et al., 2008) . , indicating amyloid plaque deposition. Except for age, demographic characteristics and cognitive scores were similar between the Ab 42 groups (Table 1) . The absolute duration between actigraphy recording and lumbar puncture, between actigraphy recording and psychometric testing, and between lumbar puncture and psychometric testing were all less than 1 year on average (Table 1) . The order of the three procedures occurred in all six possible combinations, with 59% having lumbar puncture prior to actigraphy, 53% having psychometric testing prior to actigraphy, and 46% having psychometric testing prior to lumbar puncture.
The presence of amyloid deposition (Ab 42 <500 pg mL À1 ) worsened total SRT scores by À0.14 points in the unadjusted model, but this effect was not significant after adjustment. Amyloid deposition worsened TMB performance by 18.6 s (95% CI 6.89-30.29), and this difference remained significant after adjustment for covariates (Table 1) .
Sleep efficiency alone had no significant effect on any cognitive test, before or after adjustment for covariates. However, the interaction term of sleep efficiency and Ab 42 status had a significant effect on total SRT scores, before (b = 0.030, 95% CI 0.010-0.049, P = 0.003) and after (b = 0.026, 95% CI 0.006-0.046, P = 0.011) adjustment. The interaction term did not have a significant effect on any of the other psychometric test scores. This finding indicates that worse sleep efficiency in the presence of amyloid deposition has negative effects specifically on memory performance (Fig. 1a) . In a secondary analysis, total sleep time alone had no significant effect on any cognitive test, before or after adjustment for covariates. The interaction term of total sleep time and Ab 42 status had a weak effect on total SRT scores after adjustment for covariates (b = À0.001, 95% CI À0.001 to 0.000, P = 0.010; Fig. 1b) .
DISCUSSION
We assessed the interaction of sleep and amyloid deposition on psychometric performance. We found that amyloid deposition, as assessed by CSF Ab 42 levels, and sleep efficiency interact in their effects on memory performance as measured by total SRT scores, even though amyloid deposition and sleep measures did not have individual effects on memory performance. Amyloid deposition was associated with worse performance on TMB, a test of executive function, but not after adjustment for age and other covariates. There was no significant independent effect of sleep efficiency or total sleep time on the other psychometric tests assessed in this cognitively normal population.
While worse sleep quality has been associated with worse psychometric performance in older adults (Yaffe et al., 2015) , no studies have examined the possible interaction of amyloid deposition and sleep quality on psychometric performance. This study is the first to report an interaction between CSF AD biomarkers and sleep efficiency on psychometric performance in cognitively normal adults, even after adjustment for covariates, including age and apolipoproteinE-e4 status.
The relationship between sleep, cognition and AD pathology is complex. Our results suggest that worse sleep is associated with worse memory function only when amyloid deposition is present. Alternatively, the amyloid deposition may alter or magnify the effects of sleep disturbance on memory performance. Cortical amyloid deposition has been associated with memory consolidation impairment not directly, but through impairment in non-REM slow-wave activity (Mander et al., 2015) . A possible mechanism underlying our results may be that decreased sleep efficiency may be associated with decreased non-REM slow-wave activity, leading to worse memory performance in those with amyloid deposition. Improving sleep efficiency and consolidation may lead to increased non-REM slowwave activity, which, in turn, may improve memory performance. Additionally, improved sleep efficiency may mitigate the development of tau-related neurofibrillary tangle pathology in those positive for the apolipoproteinE-e4 allele (Lim et al., 2013) .
Strengths of our study include objective sleep measures, extensive psychometric testing and known CSF AD biomarkers in a well-defined cohort. The average time between all measurements was less than 1 year. In a cognitively normal population with cognitive status determined not by psychometric testing but by Clinical Dementia Rating scale, it is unlikely that significant deficits in psychometric testing would develop during this short period. Limitations of this study include the small sample size. There were also no polysomnographic data to determine whether obstructive sleep apnea or other primary sleep disorders caused poor sleep efficiency or reduced total sleep time. However, body mass index, which is correlated with obstructive sleep apnea, was included as a covariate in analysis. Due to the small sample size, mood and anxiety disorders were also not assessed. Additionally, the overall good performance on psychometric tests from this well-educated, cognitively normal group may have contributed to higher scores and therefore reduced effect sizes.
Despite these limitations, we did identify effects of sleep on psychometric performance, when taking amyloid deposition status into account. Longitudinal follow-up will be needed to determine whether these effects become more pronounced over time. Previous epidemiological studies have shown that poor sleep may contribute to worse cognitive performance, but these studies did not include data on amyloid deposition and may have included those with mild cognitive impairment (Scullin and Bliwise, 2015) . Our results suggest that the effect of early AD pathology on cognitive performance may vary as a function of sleep. Future studies that assess more detailed sleep parameters, AD biomarkers and longitudinal cognitive trajectories will be necessary to determine the contribution of sleep to the progression from preclinical to clinical AD.
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